What is the 13F Pro Quality Score for MCK?

13F Pro ranks MCKESSON CORP (MCK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MCK's current score at https://13fpro.ai/company/MCK (free sign-up required for the full ranking).

Which hedge funds own the most MCK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MCK include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MCK as soon as new 13F filings post.

Where does 13F Pro source MCK data?

All MCKESSON CORP fundamentals and ownership data come directly from SEC EDGAR. MCKESSON CORP files with the SEC under CIK 927653. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MCK in?

MCKESSON CORP (MCK) is classified in the Consumer Staples sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/consumer-staples.

What drives MCK's revenue?

Per MCKESSON CORP's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: North American Pharmaceutical ($86.8B, +5% YoY); Oncology & Multispecialty ($14.2B, +33% YoY); Medical-Surgical Solutions ($2.8B, +4% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MCK.

What are MCK's largest expenses?

MCKESSON CORP's latest 10-Q reports these as the largest expense items: Cost of sales ($101.7B, vs. $94,548M prior year); Selling, distribution, general, and administrative ($2.3B, +3% YoY); Restructuring, impairment, and related charges, net ($136M, +189% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2027 (quarter ended June 30, 2026).

How often is MCK research updated on 13F Pro?

MCK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MCKESSON CORP(MCK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Consumer Staples →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 927653 MCK stock profile & AI dashboard →

13F Pro Quality Score

63.4/100

Rank #619 of 2,961 stocksTOP 25%

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

70.1/100

Profitability

38.4/100

Balance Sheet

71.4/100

Earnings Quality

54.1/100

Free Cash Flow

30.9/100

Institutional Flow

63.7/100

Revenue Scale

99.7/100

Dilution Risk

89.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MCK Scores 63/100

exact factor attribution · 2026-09-11

MCK's composite is driven by scale and revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.5 pts

100th pct

Revenue growth

+4.0 pts

70th pct

Capital efficiency

+2.1 pts

71th pct

Shareholder dilution

+1.9 pts

89th pct

Earnings growth

+1.3 pts

76th pct

Institutional flow

+0.7 pts

64th pct

Earnings quality

+0.4 pts

54th pct

Profitability

-1.7 pts

38th pct

Free cash flow

-2.9 pts

31th pct

Latest change (2026-08-08): 64 → 60 · ↓ Revenue growth 77→58

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MCK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MCKESSON CORP (MCK), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores MCK at 63.4/100 on a 32-signal composite quality model, placing it at rank #619 of 2,961 stocks — the top 25% of the AI-ranked universe. MCK scores in the top quartile across revenue scale (99.7). Areas of concern include free cash flow (30.9) and profitability (38.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), MCKESSON CORP reports quarterly revenue of $105.4B, net income of $614.0M, an operating margin of 1.3%. Top institutional holders of MCK by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. MCK trades on the NYSE exchange and files with the SEC under CIK 927653. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MCK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MCKESSON CORP directly from SEC EDGAR. MCKESSON CORP's 13F Pro composite quality score has ranged between 42 and 66 since 2021, currently 63.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about MCKESSON CORP

Quirks, history, and lore behind MCK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. large-cap company · operates in healthcare supply chain · listed on the NYSE · headquartered in Texas.
2
The Numbers
Annual revenue north of $275 billion, making it one of the largest companies in America by revenue — yet most people have never heard of it.
3
The History
Traces its roots back to 19th-century San Francisco as a drug wholesaler, surviving earthquakes, prohibition, and a century of healthcare upheaval to become a distribution titan.
4
The Secret
It doesn't make drugs — it moves them, distributing pharmaceuticals to hospitals, pharmacies, and healthcare providers across North America and beyond.
5
The Lore
The company paid out billions in opioid settlement funds as one of the major distributors implicated in the U.S. opioid crisis — a defining and sobering chapter in its modern history.
6
The Giveaway
Its three-letter ticker is a nod to its Scottish-American founder, and it remains the largest pharmaceutical distributor in North America — the unseen middleman in nearly every U.S. prescription.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving MCK's Business? Latest 10-Q Breakdown

✓ 31/31 datapoints verified

AI-extracted from MCKESSON CORP's 10-Q filed 2026-08-05 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenues rose 8% to $105.4B on North American Pharmaceutical and Oncology & Multispecialty growth, but net income attributable to McKesson fell 22% to $614M as a $374M redeemable noncontrolling interest redemption-value adjustment cut diluted EPS to $5.15.

Biggest Revenue Drivers

North American Pharmaceutical$86.8B+5% YoY

Higher volumes from institutional and retail national account customers, partly offset by branded price decreases and branded-to-generic conversions

Oncology & Multispecialty$14.2B+33% YoY

Primarily driven by higher specialty pharmaceutical sales in provider solutions

Biggest Revenue Drivers

Total revenue: $105.4B+8% YoY

North American Pharmaceutical$86.8B+5% YoY

Higher volumes from institutional and retail national account customers, partly offset by branded price decreases and branded-to-generic conversions

Oncology & Multispecialty$14.2B+33% YoY

Primarily driven by higher specialty pharmaceutical sales in provider solutions

Medical-Surgical Solutions$2.8B+4% YoY

Extended care sales up $79 million and ambulatory care sales up $35 million on underlying business growth

Prescription Technology Solutions$1.6B+9% YoY

Primarily due to increased volumes from third-party logistics

Largest Expense Items

Cost of sales$101.7Bvs. $94,548M prior year

Rose with volume; gross profit margin improved to 3.50% from 3.35%

Selling, distribution, general, and administrative$2.3B+3% YoY

Higher expenses to support volumes, including $68 million of net charges for the planned Medical-Surgical Solutions separation

Restructuring, impairment, and related charges, net$136M+189% YoY

Includes $61 million in Prescription Technology Solutions for asset impairments and severance, plus $50 million at Corporate

Interest expense$77M+57% YoY

Higher average loan balances, primarily driven by the MMS Credit Agreement

Margins: Gross profit margin expanded 15 bp to 3.50% on North American Pharmaceutical volume and Oncology specialty growth, while operating expenses fell to 2.25% of revenues from 2.29%.

Watch Items from the Filing

Total opioid-related litigation liability of $5.7B at June 30, 2026, with $496 million paid in July 2026 and Cabell County/Huntington claims remanded after a Fourth Circuit reversal.
Net income attributable to noncontrolling interests jumped to $418M from $47M, including $293 million and $81 million redemption-value charges for Medical-Surgical Solutions and Core Ventures.
Medical-Surgical Solutions operating profit fell 45% to $122M and margin dropped 385 bp to 4.33% on separation charges and weaker ambulatory care contribution.
Total debt rose to $9.7B from $6.5B on $3.2B of MMS term loans; total deficit widened to $(3.9)B and debt-to-capital reached 156.0%.
Returned $2.6B to shareholders via $2.5B of buybacks and $102 million of dividends; Board added $5.0B authorization and raised the quarterly dividend to $0.94.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$105.4B

Net Income

Q2 2026

$614.0M

Free Cash Flow

Q2 2026

$-332.0M

Operating Margin

Q2 2026

1.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+12.4% YoY

$403.43BFY 2026

FY23 $276.71BFY24 $308.95BFY25 $359.05BFY26 $403.43B

Net Income

+44.5% YoY

$4.76BFY 2026

FY23 $3.56BFY24 $3.00BFY25 $3.29BFY26 $4.76B

Operating Income

+40.5% YoY

$6.21BFY 2026

FY23 $4.38BFY24 $3.91BFY25 $4.42BFY26 $6.21B

EPS (Diluted)

+49.2% YoY

$38.38FY 2026

FY23 $25.03FY24 $22.39FY25 $25.72FY26 $38.38

Total Assets

+9.6% YoY

$82.32BFY 2026

FY23 $62.32BFY24 $67.44BFY25 $75.14BFY26 $82.32B

Total Debt

+13.8% YoY

$7.79BFY 2026

FY23 $6.56BFY24 $5.68BFY25 $6.84BFY26 $7.79B

Op. Cash Flow

+1.2% YoY

$6.16BFY 2026

FY23 $5.16BFY24 $4.31BFY25 $6.08BFY26 $6.16B

Free Cash Flow

+3.1% YoY

$5.72BFY 2026

FY23 $4.60BFY24 $3.63BFY25 $5.55BFY26 $5.72B

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$403.43B +12.4%	$359.05B +16.2%	$308.95B +11.7%	$276.71B +4.8%	$263.97B +10.8%	$238.23B
Net Income	$4.76B +44.5%	$3.29B +9.8%	$3.00B -15.7%	$3.56B +219.6%	$1.11B +124.5%	$-4.54B
Operating Income	$6.21B +40.5%	$4.42B +13.1%	$3.91B -10.8%	$4.38B +115.0%	$2.04B +140.4%	$-5.04B
EPS (Diluted)	$38.38 +49.2%	$25.72 +14.9%	$22.39 -10.5%	$25.03 +246.2%	$7.23 +125.6%	$-28.26
Total Assets	$82.32B +9.6%	$75.14B +11.4%	$67.44B +8.2%	$62.32B -1.5%	$63.30B -2.6%	$65.02B
Total Debt	$7.79B +13.8%	$6.84B +20.5%	$5.68B -13.5%	$6.56B -1.7%	$6.68B -15.4%	$7.89B
Operating Cash Flow	$6.16B +1.2%	$6.08B +41.1%	$4.31B -16.4%	$5.16B +16.4%	$4.43B -2.4%	$4.54B
Free Cash Flow	$5.72B +3.1%	$5.55B +53.0%	$3.63B -21.2%	$4.60B +13.7%	$4.05B -1.1%	$4.09B

Get alerted when MCK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MCKESSON CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MCK

BlackRock, Inc.
$8.2B10,795,054 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.9B7,853,137 sh
STATE STREET CORP
$4.3B5,727,118 sh
MORGAN STANLEY
$4.0B5,306,142 sh
FRANKLIN RESOURCES INC
$2.2B2,905,114 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.2B2,873,217 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.1B2,822,155 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$1.9B2,446,386 sh
FMR LLC
$1.6B2,130,288 sh
ALLIANCEBERNSTEIN L.P.
$1.5B1,686,993 sh

Fund	Value	Shares
BlackRock, Inc.	$8.2B	10,795,054
VANGUARD CAPITAL MANAGEMENT LLC	$5.9B	7,853,137
STATE STREET CORP	$4.3B	5,727,118
MORGAN STANLEY	$4.0B	5,306,142
FRANKLIN RESOURCES INC	$2.2B	2,905,114
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.2B	2,873,217
GEODE CAPITAL MANAGEMENT, LLC	$2.1B	2,822,155
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$1.9B	2,446,386
FMR LLC	$1.6B	2,130,288
ALLIANCEBERNSTEIN L.P.	$1.5B	1,686,993

Companies Similar to MCK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CAH

CARDINAL HEALTH INC

AI score

Very similar · 38 shared holders

WCM INVESTMENT MANAGEMENT, LLC NORDEA INVESTMENT MANAGEMENT AB Robeco Institutional Asset Management B.V.

COR

Cencora, Inc.

AI score

Very similar · 32 shared holders

Boston Partners Carmignac Gestion NORDEA INVESTMENT MANAGEMENT AB

PEP

PEPSICO INC

AI score

Very similar · 33 shared holders

NORDEA INVESTMENT MANAGEMENT AB National Pension Service WORLDQUANT MILLENNIUM ADVISORS LLC

CTVA

Corteva, Inc.

AI score

Very similar · 35 shared holders

WCM INVESTMENT MANAGEMENT, LLC Swedbank AB Clearbridge Investments, LLC

COCA COLA CO

AI score

Very similar · 37 shared holders

Boston Partners NORDEA INVESTMENT MANAGEMENT AB National Pension Service

MDLZ

Mondelez International, Inc.

AI score

Very similar · 26 shared holders

Capital International Investors National Pension Service NORDEA INVESTMENT MANAGEMENT AB

PROCTER & GAMBLE Co

AI score

Very similar · 31 shared holders

National Pension Service Swedbank AB Capital International Investors

MNST

Monster Beverage Corp

AI score

Shared smart-money ownership · 31 shared holders

Robeco Institutional Asset Management B.V.National Pension Service Clearbridge Investments, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Consumer Staples Companies

View all Consumer Staples →

ABEV

AMBEV S.A.

ABVE

Above Food Ingredients Inc.

ACI

Albertsons Companies, Inc.

ADM

Archer-Daniels-Midland Co

AFRI

Forafric Global PLC

AGCC

Agencia Comercial Spirits Ltd.

AGRO

Adecoagro S.A.

AGRZ

Agroz Inc.

Put MCK on your watchlist

Track score changes the day MCKESSON CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MCK a good stock to buy?

13F Pro's AI-powered analysis of MCKESSON CORP (MCK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MCK are available on the MCK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MCK is classified as a large company.

Which hedge funds own MCK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MCK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MCKESSON CORP's investment landscape.